AMGN — Amgen Inc.

Amgen Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $8.0 billion, a 4% increase year-over-year.
• Product Sales Growth: 4% driven by a diversified portfolio; 16 products achieved double-digit sales growth.
• Non-GAAP Operating Margin: 45%.
• Free Cash Flow: $1.5 billion generated in the quarter.
• R&D Spending: Increased by 16% year-over-year, reflecting investments in late-stage pipeline products.
• Dividend: Increased by 6% to $2.52 per share.

2. Strategic Updates and Business Highlights

• Key Growth Drivers: Six products (including Repatha, EVENITY, and TEZSPIRE) accounted for 70% of sales, growing 24% collectively.
• Repatha: Sales of $876 million, up 34% year-over-year, bolstered by updated treatment guidelines and strong physician response to recent clinical data.
• MariTide: Continued focus on obesity and diabetes treatment; new Phase III studies initiated for maintenance therapy and switching from weekly injectables.
• Innovative Oncology Portfolio: Grew 25% year-over-year, with IMDELLTRA emerging as a standard of care in small cell lung cancer.
• Biosimilars: Generated $835 million in sales, with a 14% year-over-year growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $37.1 billion - $38.5 billion.
• Non-GAAP EPS Guidance: Increased to $21.70 - $23.10.
• Operating Margin: Expected to remain around 45% - 46% for the full year.
• Capital Expenditures: Anticipated to be approximately $2.6 billion, focusing on manufacturing capacity for MariTide.

4. Bad News, Challenges, or Points of Concern

• Sales Erosion: Prolia and XGEVA combined sales decreased by 32% year-over-year due to loss of exclusivity and increased competition from biosimilars.
• Regulatory Challenges: Ongoing tax litigation with the IRS could materially impact financial statements; draft notice of proposed adjustments received for tax years 2016-2018.
• Competition: Increased competition in the obesity treatment market and from biosimilars poses risks to market share and pricing.

5. Notable Q&A Insights

• MariTide Studies: Questions about the design of switching studies were addressed, with a focus on patient convenience and potential efficacy.
• IMDELLTRA's Future: Discussion on the transition to frontline therapy and collaboration with the FDA on innovative trial designs to enhance patient access.
• Olpasiran's Positioning: Confidence expressed in olpasiran's unique efficacy in targeting Lp(a) levels, independent of other therapies.
• Cash-Pay Model: The AmgenNow program is gaining traction, but cash-pay patients remain a small percentage of total sales.
• Dazodalibep Development: Split Phase III studies for Sjogren's disease were justified based on observed clinical activity, with expectations for results later in the year.

Overall, Amgen reported a solid first quarter with strong growth in key product areas and a positive outlook for the year, despite facing challenges from patent expirations and regulatory scrutiny.